Avalo Therapeutics News and Activities

Avalo Therapeutics is a company listed under the stock ticker AVTX (US).

View the org chart displaying its 20 main executives

Most searched biographies at Avalo Therapeutics

• Garry Neil, Chief Executive Officer
• Mitchell Chan, Director
• Michael Heffernan, Chairman of the Board

Popular executive movements at Avalo Therapeutics

• Garry Neil who was Chairman of the Board and Chief Executive Officer, becomes Chief Executive Officer  (posted on March 26 2025).
• Michael Heffernan has joined the company as Chairman of the Board  (posted on March 26 2025).
• Jennifer Riley has joined the company as Chief Strategy Officer  (posted on January 2 2025).

Create your alert
to follow the executive moves at Avalo Therapeutics.

Avalo Therapeutics has 2,340 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Biogen (United States (USA)).

Popular M&A news in Biotechnology

• Regeneron Pharmaceuticals has announced the acquisition of 23andMe  (posted on May 20 2025).
• Stylus Medicine has just announced a $85 Million fundraising (posted on May 16 2025).
• Azafaros has just announced a $132 Million fundraising (posted on May 15 2025).

Popular contacts in Biotechnology

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships at WIRB-Copernicus Group
• Deepika Verma - Associate Director of Data Science and Digitalization at Wheeler Bio
• Steven Gillis - Chairman of the Board at VBI Vaccines

Learn more about the Biotechnology industry

Press releases by Avalo Therapeutics

• Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer :: Avalo Therapeutics, Inc. (AVTX)
• Avalo Therapeutics to Present at Upcoming Investor Conferences :: Avalo Therapeutics, Inc. (AVTX)
• Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants :: Avalo Therapeutics, Inc. (AVTX)
• Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates :: Avalo Therapeutics, Inc. (AVTX)
• Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa :: Avalo Therapeutics, Inc. (AVTX)
• Avalo Announces Participation in September Investor Conferences :: Avalo Therapeutics, Inc. (AVTX)
• Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer :: Avalo Therapeutics, Inc. (AVTX)
• Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates :: Avalo Therapeutics, Inc. (AVTX)
• Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa :: Avalo Therapeutics, Inc. (AVTX)
• Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit :: Avalo Therapeutics, Inc. (AVTX)
• View more press releases Close

Social media about Avalo Therapeutics

• Avalo Therapeutics on Wikipedia, Google News & Yahoo Finance
• Avalo Therapeutics on LinkedIn, Twitter & YouTube